Patent Description:
Self-emulsifying systems used in pharmaceutical applications to increase the solubility of insoluble active ingredients which, due to this characteristic, are poorly bioavailable (<NPL>) are extensively studied in the literature. Lipid matrices for improved drug delivery have also been investigated (<NPL>).

The systems studied are defined as "Self-Emulsifying Drug Delivery Systems" (SEDDS) and are characterized by the ability to generate sufficiently stable emulsions in water under mild stirring conditions. This differentiates them from the classic emulsions in which the homogeneous dispersion is obtained through vigorous stirring. This feature is very important because inside the body, an emulsion can only be formed through the mild mechanical movements applied by the intestinal motion.

Self-emulsifying systems involve the use of oily substances, emulsifying substances, and co-emulsifying substances.

The components of these systems are known to have the following reasons for use:.

The active ingredient included in these systems is generally characterized by poor solubility in water and poor bioavailability in the body following intake. Making an emulsion of the active dissolved in the oily phase involves the solubilization of the active in water, moreover it generally involves an increase in the bioavailability of the active thus delivered (<NPL>).

In the paper by Mauro Serratoni et al (<NPL>) the development of solid self-emulsifying systems (SSEDDS) through extrusion/spheronization technique is reported. In this work, the possibility of producing self-emulsifying systems was evaluated starting from a liquid emulsion deposited on a solid carrier (microcrystalline cellulose). The system is then subjected to the extrusion/spheronization process. This process allows to obtain pellets (having a size of <NUM> - <NUM>) with self-emulsifying capacity, which allow to obtain an increased release of two model molecules characterized by poor solubility in water (methyl-paraben and propyl-paraben).

Based on the state of the art illustrated herein, the inventors understood that the prior art systems left unsolved the problem of making a solid self-emulsifying system capable of creating a liquid emulsion at body temperature. In fact, there are many self-emulsifying liquid systems, transformed into solids via inclusion in solid casings (<NPL>) or supported on adsorbent solid carriers (<CIT>), but to date there are no solid systems, at room temperature, which have self-emulsifying capacity when taken into the organism.

The object of the present invention is therefore to overcome the prior art and thus provide a self-emulsifying system that is solid at room temperature, and which is however capable of carrying out its function at a temperature higher than the ambient one, that is, at body temperature.

The inventors have therefore surprisingly made a self-emulsifying system that is in a solid state at room temperature but is able to melt and form an emulsion when being at body temperature inside the organism, under the mild stirring provided by peristaltic movements.

The invention therefore concerns a self-emulsifying solid particle at body temperature comprising.

The solid particle of the invention advantageously comprises also from <NUM> to <NUM>%, with respect to the weight of the particle, of at least one antioxidant agent.

The solid particle of the invention may advantageously comprise at least one poorly soluble/bioavailable active ingredient.

In the present invention, when the definition of "poorly soluble/bioavailable active ingredient" is used, it is intended to mean an active ingredient falling in the BCS (Biopharmaceutical Classification System) Class <NUM>, <NUM> or <NUM>, as will be detailed in the following detailed description.

Advantageously, the present invention therefore allows to have solid particles, and thus characterized by all the advantages of handling and workability typical of powders, but capable of forming a stable emulsion when they are at body temperature (<NUM> - <NUM>) and are subjected to the mild peristaltic movements typical of the gastrointestinal system. The self-emulsifying solid particles may advantageously comprise at least one active ingredient and therefore may also be defined as microencapsulates which, by their constitution, are solid at room temperature, but due to their formulation peculiarities, the particles object of this invention are characterized by the self-emulsifying capacity, therefore they generate an emulsion, when taken into the body, being at body temperature and under mild stirring caused by peristaltic movements. This ability enables to suspend and/or emulsify the insoluble or poorly soluble active ingredients in the body's aqueous solutions.

Disclosed, but not claimed, is a process for the preparation of at least one self-emulsifying solid particle at body temperature comprising the following steps:.

Preferably, in b), from <NUM> to <NUM>% by weight, with respect to the weight of the initial formulation, of at least one antioxidant agent is added.

Disclosed, but not claimed, is the solid particle obtainable from the process disclosed, which is solid at room temperature and self-emulsifying at a body temperature comprised in the range from <NUM> to <NUM>.

Said solid particle of the invention has a median diameter comprised between <NUM> and <NUM>, as measured by particle size analysis through a sieve method using an ENDECOTTS - OCTAGON <NUM> vibrating screen.

Advantageously, the present invention allows to have solid particles, and thus characterized by all the advantages of handling and workability typical of powders, but capable of forming a stable emulsion when they are at body temperature (<NUM> - <NUM>) and are subjected to the mild peristaltic movements typical of the gastrointestinal system. The solid particles may also be defined as microencapsulates which, by their constitution, are solid at room temperature, but due to the formulation peculiarities, the particles object of this invention are characterized by a self-emulsifying capacity, therefore they generate an emulsion, when taken in the organism, being at body temperature and under mild stirring caused by peristaltic movements. This ability allows to suspend and/or emulsify the insoluble or poorly soluble active ingredients in the body's aqueous solutions.

In yet another aspect, the invention relates to a microencapsulate comprising the self-emulsifying solid particle at body temperature, and at least one poorly soluble/bioavailable active ingredient.

As will be apparent from the experimental part that follows, the particle obtainable from the process disclosed, solid at room temperature and self-emulsifying at body temperature in the range from <NUM> to <NUM>, when in the presence of body temperature, is dispersed in intestinal fluids having neutral pH, thus generating micelles having a hydrodynamic diameter in the range from <NUM> to <NUM> (as measured by dynamic light scattering (DLS)) and which remain stable for up to <NUM> minutes.

The invention therefore allows to have the administration/delivery of at least one active ingredient as a solid product, characterized by the advantages of this physical state, such as ease of transport, storage and processing (e.g. making tablets, capsules, sachets, stick-packs, etc.), thus allowing to increase the solubility, and therefore the bioavailability, of normally insoluble pharmaceutical or nutraceutical active ingredients characterized by poor body absorption.

In another aspect, therefore, the invention relates to the self-emulsifying solid particle for use in the delivery of active ingredients.

The invention therefore concerns a self-emulsifying solid particle at body temperature comprising:.

In the present invention, when the definition of "poorly soluble/bioavailable active ingredient" is used, it is intended to mean an active ingredient falling in the BCS (Biopharmaceutical Classification System) Class <NUM>, <NUM> or <NUM>.

The active ingredients are divided into BCS (Biopharmaceutical Classification System) classes based on solubility and absorption (<NPL>):.

The self-emulsifying solid particle of the invention comprises from <NUM>% to <NUM>% by weight, with respect to the weight of the particle, of at least one fatty substance having a melting point in the range from <NUM> to <NUM>, wherein said at least one fatty substance having a melting point in the range from <NUM> to <NUM> is selected from the group consisting of glycerol behenate, stearic acid, magnesium stearate, vegetable stearin, bees wax, carnauba wax and candelilla wax.

Preferably the fatty substance having a melting point in the range from <NUM> to <NUM> is in the range from <NUM>% to <NUM>%, more preferably from <NUM>% to <NUM>%, even more preferably from <NUM>% to <NUM>% with respect to the weight of the particle.

Said at least one fatty substance having a melting point in the range from <NUM> to <NUM> is selected from the group consisting of glycerol behenate, stearic acid, magnesium stearate, vegetable stearin, bees wax, carnauba wax and candelilla wax. In an advantageous and preferred embodiment, it is glycerol behenate.

The solid particle comprises from <NUM>% to <NUM>% by weight, with respect to the weight of the particle, of at least one fatty substance having a melting point lower than <NUM>, wherein said at least one fatty substance having a melting point lower than <NUM> is selected from the group consisting of cocoa butter, margarine, butter, olive oil, linseed oil, grape seed oil and medium chain triglycerides (MCT). Preferably, the at least one fatty substance having a melting point lower than <NUM> is in the range from <NUM>% to <NUM>%, more preferably from <NUM>% to <NUM>%, even more preferably from <NUM>% to <NUM>% by weight, with respect to the weight of the solid particle.

Said at least one fatty substance having a melting point lower than <NUM> is preferably selected from the group consisting of cocoa butter, margarine, butter, olive oil, linseed oil, grape seed oil and medium chain triglycerides (MCT), more preferably cocoa butter.

The solid particle also comprises at least one emulsifier in an amount in the range from <NUM>% to <NUM>%. Said amount is preferably in the range from <NUM> to <NUM>%, more preferably from <NUM> to <NUM>%, even more preferably from <NUM> to <NUM>% with respect to the weight of the particle.

According to the invention, the at least one emulsifier is a polysorbate (Polyoxyethylene Sorbitan monooleate). Preferably said at least one emulsifier is selected from the group consisting of Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>. More preferably, the emulsifier is Polysorbate <NUM> commercially known as TWEEN <NUM>.

The solid particle also preferably comprises from <NUM> to <NUM>% of at least one antioxidant agent with respect to the weight of the particle. More preferably, said at least one antioxidant agent is in the range from <NUM> to <NUM>% by weight, with respect to the weight of the particle. The at least one antioxidant agent is advantageously and preferably Vitamin E. More preferably the at least one antioxidant agent is a mixture of two or more from alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol.

Advantageously, the present invention thus allows to have solid particles, therefore characterized by all the advantages of handling and workability typical of powders, but capable of forming a stable emulsion when they are at body temperature (<NUM> - <NUM>) and are subjected to the mild peristaltic movements typical of the gastrointestinal system. The solid particles may advantageously comprise at least one active ingredient and also be defined as microencapsulates which, by their constitution, are solid at room temperature, but due to the formulation peculiarities, are characterized by a self-emulsifying capacity, therefore they generate an emulsion, when taken in the organism, being at body temperature and under mild stirring caused by peristaltic movements. This ability allows to suspend and/or emulsify the insoluble or poorly soluble active ingredients in the body's aqueous solutions.

The invention therefore concerns a microencapsulate comprising the self-emulsifying solid particle of the invention and one or more poorly soluble/bioavailable active ingredients.

Said at least one active ingredient is preferably a dry, soft and fluid plant extract for nutraceutical use (Annex <NUM> to the Ministerial Decree of <NUM> August <NUM> on the regulation of the use of plant substances and preparations in food supplements, as updated with the Decree of <NUM> January <NUM> and lastly with Decree of <NUM> July <NUM>) and/or pharmaceutical use; a substance permitted for use in food (nutrients and other substances with a nutritional or physiological effect (Revision September <NUM>) - Ministry of Health)); vitamins and minerals for food use (COMMISSION REGULATION (EC) No. <NUM>/<NUM> of <NUM> November <NUM>), vitamins for pharmaceutical use; food substances included in the Novel Food regulation (COMMISSION IMPLEMENTING REGULATION (EU) <NUM>/<NUM> of <NUM> December <NUM>) and of which there is no history of consumption since before <NUM> in the country of use; pharmaceutical grade active ingredients characterized by reduced solubility, reduced absorption and/or reduced solubility and absorption.

Disclosed, but not claimed, is a process for the preparation of at least one solid self-emulsifying particle at body temperature comprising the following steps:.

Advantageously, the process comprises a step c), between step b) and step d), which provides for the addition of at least one poorly soluble/bioavailable active ingredient.

The process involves a) preparing an initial formulation by mixing the following ingredients:.

Preferably the fatty substance having a melting point in the range from <NUM> to <NUM> is in the range from <NUM>% to <NUM>%, more preferably from <NUM>% to <NUM>%, even more preferably from <NUM>% to <NUM>% with respect to the weight of the initial formulation.

In step a), the initial formulation comprises from <NUM>% to <NUM>% by weight, with respect to the initial formulation, of at least one fat substance having a melting point lower than <NUM> selected from the group consisting of cocoa butter, margarine, butter, olive oil, linseed oil, grape seed oil and medium chain triglycerides (MCT). Preferably the at least one fatty substance having a melting point lower than <NUM> is in the range from <NUM>% to <NUM>%, more preferably from <NUM>% to <NUM>%, even more preferably from <NUM>% to <NUM>% by weight, with respect to the weight of the initial formulation.

In the initial formulation there is also at least one polysorbate (Polyoxyethylene Sorbitan monooleate) in an amount in the range from <NUM>% to <NUM>%. Said amount is preferably in the range from <NUM> to <NUM>%, more preferably from <NUM> to <NUM>%, even more preferably from <NUM> to <NUM>% with respect to the weight of the initial formulation.

In step b), the final formulation is melted and brought to homogenization. Preferably step b) provides for adding from <NUM> to <NUM>% by weight, with respect to the weight of the initial formulation, of at least one antioxidant agent after homogenization and before step c).

More preferably, said at least one antioxidant agent is in the range from <NUM> to <NUM>% by weight with respect to the weight of the initial formulation.

Following step b) according to the invention, a melted mass is obtained.

In step d), the melted mass is cooled and at least one self-emulsifying solid particle is obtained.

All the preferred aspects related to the components of the emulsifying solid particle are the same as the ones in the process that allows it to be obtained, and are repeated herein only for completeness purpose of the process of the invention.

Said at least one fatty substance having a melting point lower than <NUM> is selected from the group consisting of cocoa butter, margarine, butter, olive oil, linseed oil, grape seed oil and medium chain triglycerides (MCT). More preferably it is cocoa butter.

In the initial formulation at least one emulsifier is present with respect to the weight of the initial formulation.

According to the invention, the emulsifier is a polysorbate (Polyoxyethylene Sorbitan Monooleate). Preferably said at least one emulsifier is selected from the group consisting of Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>, Polysorbate <NUM>. More preferably, the emulsifier is Polysorbate <NUM> commercially known as TWEEN <NUM>.

In step b) the final formulation is melted and brought to homogenization. In step b), after homogenization, the process preferably provides for the addition of at least one antioxidant agent in the range from <NUM>% to <NUM>% by weight, with respect to the weight of the initial formulation. The at least one antioxidant agent is advantageously and preferably Vitamin E. More preferably the at least one antioxidant agent is a mixture of two or more from alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol.

Advantageously, the process comprises a step c), between step b) and step d), which provides for the addition of at least one active ingredient having a low solubility/bioavailability.

Preferably, therefore, the process allows the delivery and solubility increase of poorly soluble/bioavailable active ingredients.

The process and the solid particle at room temperature and self-emulsifying at body temperature, therefore, allow the delivery and administration of active ingredients, allowing an increase in solubility and absorption.

Step d) relates to cooling the melted mass of step b) or c) to obtain at least one self-emulsifying solid particle.

Surprisingly, the cooling and the peculiarities of the initial formulation allow to obtain a particulate which is solid at room temperature but, thanks to the composition of the melted mass, melts at body temperature (<NUM>-<NUM>) thus allowing the formation of an emulsion by means of the mild peristaltic movements of the body's gastrointestinal system, with a resulting improvement in the solubility of active ingredients included in a category defined as insoluble.

Such step d) may preferably and advantageously take place by cooling said melted mass by means of a spray cooling plant, thus obtaining at least one self-emulsifying solid particle. The spray cooling technique is commonly defined in at least three ways, namely spray cooling, spray chilling or spray congealing. The spray cooling technique inside a refrigerated cell allows to drastically lower the temperature of the particulate matter obtained from the melted mass during the flight time, and thus obtain the self-emulsifying system in the solid state.

In addition to the spray cooling technique, the cooling step d) may also take place through melt granulation and melt extrusion, melt extrusion/spheronization.

Step d) may therefore take place by means of melt granulation. After obtaining the melt, and the optional and preferred addition of at least one active ingredient, the temperature lowering allows to obtain solid granules with self-emulsifying capacity in aqueous medium at body temperature.

Alternatively, step d) may take place by means of melt extrusion/spheronization. In this case the melted mass is forced through a perforated septum under controlled temperature, flow, and pressure. With this technique, an extrudate having well-defined size is obtained, which can be controlled through the working parameters used. The extrudates produced in this way may be transferred out of the plant on a spheronizing plate which allows to obtain a particulate having a spherical shape and with predetermined size.

The process, and thus the solid particle, may include additives.

Among additives to be added before step d), and which are therefore present in the solid particle, dyes, coating agents, flavorings and sweeteners can be mentioned.

Among dyes, titanium dioxide, calcium carbonate and iron oxides can be mentioned. Among glazing agents, hydroxypropylmethylcellulose, sodium alginate, ethylcellulose, polyvinyl alcohol, poly(butylmethacrylate, (<NUM>-dimethylaminoethyl) methacrylate, methyl methacrylate) <NUM>: <NUM>: <NUM>, poly(ethyl acrylate, methyl methacrylate) <NUM> : <NUM>, poly(methacrylic acid, methyl methacrylate) <NUM>: <NUM>, poly(methacrylic acid, ethyl acrylate) <NUM> : <NUM>, poly(methacrylic acid, methyl methacrylate) <NUM> : <NUM>, poly(methyl acrylate, methyl methacrylate, methacrylic acid) <NUM> : <NUM>: <NUM>, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) <NUM>: <NUM> : <NUM>, poly(ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) <NUM> : <NUM> : <NUM>.

Among aromas, natural aromas and/or synthetic aromas can be mentioned. Among sweeteners, sorbitol, mannitol, xylitol, erythritol, sucralose, stevia, acesulfame K, sodium cyclamate, aspartame, saccharin, dextrose, isomalt, trehalose, inositol, sucrose, fructose, dextrose, glucose, isomaltulose, neohesperidin dihydrochalcone can be mentioned.

Disclosed, but not claimed, is the solid particle obtainable from the process, which is solid at room temperature and self-emulsifying at a body temperature in the range from <NUM> to <NUM>.

The invention therefore consists in making a solid system at room temperature, but which has self-emulsifying capacity at body temperature following melting thereof, and if subjected to mild stirring, due to the peristaltic movements of the gastrointestinal tract.

The solid particles of the invention had a median diameter comprised between <NUM> and <NUM>, as measured by particle size analysis through a sieve method using an ENDECOTTS - OCTAGON <NUM> vibrating screen.

Without being bound to any theory, the inventors of the present invention believe that the lipophilic matrix, which forms a relevant part of the self-emulsifying solid particle, allows to solubilize insoluble substances in an aqueous environment, thus allowing their emulsification thanks to the presence of emulsifiers in the formulation. Furthermore, the lipophilic matrix of the initial formulation allows the dispersion of substances which, although soluble in an aqueous environment, are not very bioavailable. This system allows, therefore, to obtain suspensions of the substances of interest, favoring their absorption.

The invention therefore allows to obtain the administration/delivery of at least one active ingredient as a solid product, characterized by the advantages of this physical state, such as ease of transport, storage and processing (e.g. making tablets, capsules, sachets, stick-packs, etc.), thus allowing to increase the solubility, and therefore the bioavailability, of normally insoluble active pharmaceutical or nutraceutical ingredients characterized by poor absorption by the body.

Without being bound to any theory, the inventors believe that the self-emulsifying solid particle loaded with the at least one active ingredient to form the microencapsulate has the following mechanism of action: the active ingredients are solubilized or dispersed in the oily/hydrophobic matrix (i.e. the fatty substance having a melting point in the range from <NUM> to <NUM>/ the fatty substance having a melting point lower than <NUM>, both specifically defined) which forms the system and, when the solid particles are at a temperature equal to or higher than the body temperature, they tend to melt back to the liquid state. The presence of the emulsifier component therefore drives the formation of micelles in which the core is made of the oily/hydrophobic component (i.e. respectively the fatty substance having a melting point in the range from <NUM> to <NUM>/ the fatty substance having a melting point lower than <NUM>, both specifically defined) in which the active ingredients are dissolved or dispersed.

As will be apparent from the experimental part that follows, the solid particles of the invention, when in the presence of body temperature, get dispersed in intestinal fluids with neutral pH generating micelles having a hydrodynamic diameter in the range from <NUM> to <NUM> (as measured by dynamic light scattering (DLS)) and remain stable for up to <NUM> minutes.

Disclosed, but not claimed, is the microencapsulate of the invention for use in the treatment of a disease included in the activities of the at least one poorly soluble/bioavailable active ingredient contained in the microencapsulate. Advantageously, the at least one active ingredient is more absorbed, with a better bioavailability of the same.

The invention will now be illustrated by means of examples provided by way of nonlimiting example of the same invention.

In the experimental part that follows, the analytical methods mentioned below were used.

Disaggregation: verifies the formation of the emulsion starting from the self-emulsifying system at a temperature equal to body temperature, and subjected to mild stirring to simulate the peristatic movements of the gastrointestinal tract. Dissolution: verifies the release of the active ingredients by the self-emulsifying system.

HPLC/other technique: verifies the loading capacity of the active ingredient by the self-emulsifying solid particle.

DLS: verifies the size of the micelles of the emulsion formed from the self-emulsifying system at a temperature equal to body temperature, and subjected to mild stirring to simulate the peristatic movements of the gastrointestinal tract to evaluate the stability thereof.

The definitions of the acronyms used are given below.

A three-phase diagram was developed (shown in <FIG>) to study the concentrations of the components effective in the preparation of solid particles with self-emulsifying capacity. Examples <NUM>, <NUM> were carried out within the region highlighted in the three-phase diagram of <FIG>, to evaluate whether the ranges identified for the essential components of the initial formulation allowed the preparation of self-emulsifying solid particles.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. An amount of tocopherol mixture (containing alpha-, beta-, gamma- and delta-tocopherol) equal to <NUM> was added to the melted mass. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

The fragments obtained in Example <NUM> had an optimal mechanical strength and, when placed in the disaggregation tester, showed the formation of an emulsion. The opalescent dispersion, exposed to a light source, showed homogeneous diffusion of light, characteristic of systems with presence of emulsion.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. An amount of tocopherol mixture (containing alpha-, beta-, gamma- and delta-tocopherol) equal to <NUM> was added to the melted mass. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% RH). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of an emulsion. As in Example <NUM>, the SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water with a pH comprised between <NUM> and <NUM> at a well-defined temperature (comprised between <NUM> and <NUM>) and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

The fragments obtained in Example <NUM> have good mechanical strength and, when placed in the SOTAX DT3 disaggregation tester, show the formation of an emulsion. The opalescent dispersion, exposed to a light source, showed homogeneous diffusion of light, characteristic of systems with presence of emulsion.

With Example <NUM>, both the confirmation of the nature of the essential components and also their formulation ranges were obtained.

Specifically, the initial formulation and therefore the solid particle of the invention comprised:.

Example <NUM> and Example <NUM> performed within these ranges led to the formation of systems with self-emulsifying capacity, which remain solid at room temperature. Through the evaluation of points within the above ranges for performance in terms of emulsifying capacity, mechanical strength and handling of the particles obtained, a narrower range was then identified within which the particles obtained had optimal strength characteristics in terms of mechanical strength and self-emulsifying capacity at body temperature.

A representation of the results obtained with Experiments <NUM> and <NUM> is shown in <FIG> shows, on the left, the result of the disaggregation test carried out on three control points within the region highlighted in <FIG>; on the right there is a detail of the emulsion that is generated, highlighting the opalescent appearance thereof.

Examples <NUM>, <NUM> and <NUM> below are representative of the optimal experimental space identified in <FIG>.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. An amount of tocopherol mixture (containing alpha-, beta-, gamma- and delta-tocopherol) equal to <NUM> was added to the melted mass. The melted mass thus obtained was then sprayed by using an airbrush inside a thermostatic chamber at <NUM>. The airbrush was selected for spraying the self-emulsifying system, as it simulated the working conditions of the spray cooler used at the production level. This procedure led to the formation of a particulate having particles with a median diameter comprised between <NUM> and <NUM>, as measured by particle size analysis through a sieve method using an ENDECOTTS - OCTAGON <NUM> vibrating screen. The sieves used were the following: <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. An amount of tocopherol mixture (containing alpha-, beta-, gamma- and delta-tocopherol) equal to <NUM> was added to the melted mass. The melted mass thus obtained was then sprayed by using an airbrush inside a thermostatic chamber at <NUM>. This process led to the formation of a particulate having particles with a median diameter comprised between <NUM> and <NUM>, as measured by particle size analysis through a sieve method using an ENDECOTTS - OCTAGON <NUM> vibrating screen. The sieves used were the following: <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. An amount of tocopherol mixture (containing alpha-, beta-, gamma- and delta-tocopherol) equal to <NUM> was added to the melted mass. The melted mass thus obtained was then sprayed by using an airbrush inside a thermostatic chamber at <NUM>. This process led to the formation of particulate matter having particles with median diameter comprised between <NUM> and <NUM>, as measured by particle size analysis through a sieve method using an ENDECOTTS - OCTAGON <NUM> vibrating screen. The sieves used were the following: <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>, <NUM>. The particulate obtained in experiments <NUM>, <NUM> and <NUM> was subsequently subjected to disaggregation test to evaluate its emulsifying capacity. The analysis parameters were kept the same for all three experiments described above: an amount comprised between <NUM> and <NUM> of particulate was placed in a SOTAX DT3 disaggregation tester in a solution having a pH comprised between <NUM> and <NUM> and at a temperature comprised between <NUM> and <NUM>. The formation of an opalescent and milky dispersion and the evaluation of the homogeneous dispersion of the light source in the system containing the emulsion were taken into consideration as conditions to define whether the emulsion had formed or not. All <NUM> particulates obtained in experiments <NUM>, <NUM> and <NUM> proved effective in generating an emulsion. Furthermore, the emulsions thus obtained were monitored over time to evaluate their stability. The emulsions were kept at a temperature comprised between <NUM> and <NUM> in an oven, this to avoid the skimming of the emulsion due to system cooling.

<FIG> shows the three emulsions obtained from experiments <NUM>, <NUM> and <NUM>. The results obtained show that the solid system obtained has self-emulsifying capacity, if placed in an aqueous environment at neutral pH at a temperature compatible with that of the body. Furthermore, again in <FIG>, it can be seen how the emulsions obtained are stable for a much longer time than the residence time necessary to allow the absorption of the active ingredients in the human body.

Dispersibility analysis of the particle of the invention.

The particles of the invention, once dispersed in the body fluid, appeared as a micellar fluid. The micelles were evaluated to determine their size distribution by dynamic light scattering (DLS) when introduced into body fluids.

A sample was prepared according to Example <NUM>.

The sample was indexed as in Table <NUM> below:.

The sample was dispersed in simulated intestinal fluids (SIF) according to the model of Minekus et al. (<NUM>), whose composition is reported in Table <NUM>.

The powder sample (21LA03343) was dispersed in SIF at a final concentration of <NUM>/mL.

The particles of the invention dispersed forming micelles, and the dispersions of the micelles were incubated under gentle stirring at <NUM> and collected and analyzed after <NUM>, <NUM> and <NUM>. The micelles size distribution obtained by DLS was evaluated on at least <NUM> replicated measurements, as a function of the signal intensity alone.

The sample "21LA03343 - C-<NUM>-<NUM>-<NUM>, self-emulsifying system", under the conditions of analysis had a single peak, as shown in <FIG>. The hydrodynamic diameter of the micelles measured in the sample "21LA03343 - C-<NUM>-<NUM>-<NUM>, self-emulsifying system" after <NUM>-<NUM>-<NUM> minutes of incubation in SIF is reported in Table <NUM> below. The values are accompanied by the standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and the relative standard deviation expressed as a percentage (RSD). Table <NUM> also shows the polydispersity index of the suspension (Pdl) with standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and relative standard deviation expressed as a percentage (RSD).

With reference to <FIG>, after <NUM> minutes, the micelle peak was seen to shift towards a smaller size. The micelles reached their stability by reducing in size and stabilizing around <NUM>. The Pdl decreased with the passage of time indicating an increase in the stability of the emulsion. This index (Pdl) is comprised between O and <NUM>, the closer it is to <NUM> the more the emulsion is monodisperse; for indices equal to <NUM>, instead, the emulsion is considered totally polydisperse and therefore more unstable. The sample of the invention was therefore found to form a very stable monodisperse emulsion.

From the data obtained, it was therefore clear that the "C-<NUM>-<NUM>-<NUM>, self-emulsifying system" was dispersed in intestinal fluids with neutral pH, generating micelles of approximately <NUM> in size which were stable up to at least <NUM> minutes.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of Cocoa Butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

The fragments obtained from Example <NUM>, placed in the disaggregation tester, showed the formation of an emulsion.

The opalescent dispersion, exposed to a light source, showed homogeneous diffusion of light, characteristic of systems with presence of emulsion.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol behenate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

The fragments obtained from Example <NUM>, placed in a disaggregation tester, showed the formation of an emulsion.

The fragments obtained in Example <NUM>, placed in a disaggregation tester, showed the formation of an emulsion.

The sample was dispersed in simulated intestinal fluids (SIF) according to the model of Minekus et al. (<NUM>) whose composition is reported in Table <NUM>.

The powder sample (22LA05496) was dispersed in SIF at a final concentration of <NUM>/mL.

The particles of the invention dispersed forming micelles, and the dispersions of the micelles were incubated under gentle stirring at <NUM> and collected and analyzed after <NUM>, <NUM> and <NUM>. The size distribution of the micelles obtained by DLS was evaluated on at least <NUM> replicated measurements, as a function of the signal intensity alone.

The sample "22LA05496- C-<NUM>-<NUM>-<NUM>, self-emulsifying system", under the conditions of analysis had a single peak, as shown in <FIG>. The hydrodynamic diameter of the micelles measured in the sample "22LA05496 - C-<NUM>-<NUM>-<NUM>, self-emulsifying system" after <NUM>-<NUM>-<NUM> minutes of incubation in SIF is reported in Table <NUM> below. The values are accompanied by the standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and the relative standard deviation expressed as a percentage (RSD). Table <NUM> also shows the polydispersity index of the suspension (Pdl) with standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and relative standard deviation expressed as a percentage (RSD).

With reference to <FIG>, the micelle peak was seen to remain at constant size up to <NUM>. The micelles showed their stability already at <NUM> by stabilizing around a size of about <NUM>. The Pdl remained unchanged with the passage of time, indicating stability of the emulsion. Such index (Pdl) is comprised between <NUM> and <NUM>, the closer it is to <NUM> the more the emulsion is monodisperse; for indices equal to <NUM>, instead, the emulsion is considered totally polydisperse and therefore more unstable. The sample of the invention was therefore found to form a very stable monodisperse emulsion.

From the data obtained, it was therefore clear that the "C-<NUM>-<NUM>-<NUM>, self-emulsifying system" was dispersed in intestinal fluids with neutral pH, generating micelles of approximately <NUM> in size, which were stable up to at least <NUM> minutes.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of olive oil equal to <NUM> was added. Once the latter was completely melted, an amount of stearic acid equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of medium chain triglycerides equal to <NUM> was added. Once the latter was completely melted, an amount of Candelilla wax equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not. The fragments obtained from Example <NUM>, placed in the disaggregation tester, showed the formation of an emulsion.

A sample was prepared according to Example <NUM>.

The powder sample (22LA05498) was dispersed in SIF at a final concentration of <NUM>/mL.

The sample "22LA05498 - C-<NUM>-<NUM>-<NUM>, self-emulsifying system", under the test conditions had a single peak, as shown in <FIG>. The hydrodynamic diameter of the micelles measured in the sample "22LA05498 - C-<NUM>-<NUM>-<NUM>, self-emulsifying system" after <NUM>-<NUM>-<NUM> minutes of incubation in SIF is reported in Table <NUM> below. The values are accompanied by the standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and the relative standard deviation expressed as a percentage (RSD). Table <NUM> also shows the polydispersity index of the suspension (Pdl) with standard deviation (SD, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>, t= <NUM> n=<NUM>) and relative standard deviation expressed as a percentage (RSD).

With reference to <FIG>, it was seen that, after <NUM> minutes, the micelle peak shifted to a larger size. The micelles reached their stability by increasing in size and stabilizing around <NUM>. The Pdl remained unchanged with the passage of time, indicating a stability of the emulsion. This index (Pdl) is between <NUM> and <NUM>, the closer it is to <NUM> the more the emulsion is monodispersed; for indices equal to <NUM>, instead, the emulsion is considered totally polydisperse and therefore more unstable. The sample of the invention was therefore found to form a very stable monodisperse emulsion.

From the data obtained it was therefore clear that the "C-<NUM>-<NUM>-<NUM>, self-emulsifying system" was dispersed in intestinal fluids with neutral pH generating micelles of approximately <NUM> size which were stable up to at least <NUM> minutes.

An amount of Polysorbate <NUM> equal to <NUM> was placed in a water bath at a temperature comprised between <NUM> and <NUM>. To this, an amount of cocoa butter equal to <NUM> was added. Once the latter was completely melted, an amount of glycerol stearate equal to <NUM> was added to the melted mass. The system was kept under constant stirring throughout the process, until all the components were completely melted and homogenized. The melted mass thus obtained was then re-solidified on a surface at room temperature (about <NUM> and <NUM>% relative humidity (RH)). Subsequently, the solid obtained was reduced into fragments of homogeneous size (about <NUM> - <NUM>). A known amount of these fragments (between <NUM> and <NUM>) was subjected to disaggregation test to verify the actual formation of the emulsion. The SOTAX DT3 disaggregation tester was selected as the initial analysis tool, because it allowed the system to be placed in water under conditions similar to those of the body, i.e. at a pH comprised between <NUM> and <NUM> and at a well-defined temperature (comprised between <NUM> and <NUM>), and to replicate the mild stirring provided by the gastrointestinal peristaltic movements. The formation of an opalescent and milky dispersion was taken into consideration as a condition to define whether the emulsion had formed or not.

Claim 1:
A self-emulsifying solid particle at body temperature comprising:
- from <NUM>% to <NUM>% by weight, with respect to the weight of the particle, of at least one fatty substance having a melting point in the range from <NUM> to <NUM>,
- from <NUM>% to <NUM>% by weight, with respect to the weight of the particle, of at least one fatty substance having a melting point lower than <NUM>, and
- from <NUM> to <NUM>%, with respect to the weight of the particle, of at least one emulsifier,
wherein
said at least one fatty substance having a melting point in the range from <NUM> to <NUM> is selected from the group consisting of glycerol behenate, stearic acid, magnesium stearate, vegetable stearin, bees wax, carnauba wax and candelilla wax,
said at least one fatty substance having a melting point lower than <NUM> is selected from the group consisting of cocoa butter, margarine, butter, olive oil, linseed oil, grape seed oil and medium chain triglycerides (MCT), and the at least one emulsifier is a polysorbate (Polyoxyethylene Sorbitan Monooleate).